Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: povidone; alginic acid; citric acid monohydrate; magnesium stearate; hypromellose; purified talc; microcrystalline cellulose; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: citric acid monohydrate; magnesium stearate; povidone; alginic acid; microcrystalline cellulose; purified talc; hypromellose; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: alginic acid; povidone; microcrystalline cellulose; citric acid monohydrate; magnesium stearate; purified talc; hypromellose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Estats Units - anglès - NLM (National Library of Medicine)

physicians total care, inc. - paroxetine hydrochloride (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 12.5 mg - paroxetine hydrochloride extended-release tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine hydrochloride extended-release tablets in the treatment of a major depressive episode was established in two 12 week controlled trials of outpatients whose diagnoses corresponded to the dsm-iv category of major depressive disorder (see clinical pharmacology: clinical trials). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning and includes the presence of at least 5 of the following 9 symptoms during the same 2 week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impai

República de Sud-àfrica - anglès - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline consumer healthcare sa (pty) ltd - tablet - see ingredients - each tablet copntains paracetamol 500,0 mg

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

viatris limited - erythromycin ethylsuccinate 482mg equivalent to erythromycin 400 mg (plus 3% overage) - film coated tablet - 400 mg - active: erythromycin ethylsuccinate 482mg equivalent to erythromycin 400 mg (plus 3% overage) excipient: calcium hydrogen phosphate magnesium stearate maize starch opadry pink oy-b-34901 povidone purified talc purified water sodium starch glycolate sorbic acid - streptococcus pyogenes (group a beta-haemolytic streptococcus): upper and lower respiratory tract, skin and soft tissue infections of mild to moderate severity. when oral medication is preferred for treatment of streptococcal pharyngitis and in long term prophylaxis of rheumatic fever, erythromycin is an alternate drug of choice. when oral medication is given, the importance of strict adherence by the patient to the prescribed dosage regimen must be stressed. a therapeutic dose should be administered for at least 10 days. prevention of initial attacks of rheumatic fever: penicillin is considered to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta-haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin-allergic patients. the therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sevelamer carbonate 800mg; sevelamer carbonate 800mg - film coated tablet - 800 mg - active: sevelamer carbonate 800mg excipient: isopropyl alcohol microcrystalline cellulose opacode opadry clear propylene glycol sodium chloride zinc stearate active: sevelamer carbonate 800mg excipient: acetylated monoglycerides hypromellose e-15 hypromellose e-5 isopropyl alcohol microcrystalline cellulose opacode propylene glycol sodium chloride zinc stearate - renvela is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - iron polymaltose 370mg equivalent to iron 100mg - film coated tablet - 100 mg - active: iron polymaltose 370mg equivalent to iron 100mg excipient: crospovidone macrogol 6000 magnesium stearate microcrystalline cellulose opadry maroon oy-s-36413 - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - sodium alginate; sodium hydrogen carbonate; calcium carbonate - chewable tablet - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

polytra pty ltd - oyster shell, quantity: 1.39 g (equivalent: calcium, qty 500 mg); colecalciferol, quantity: 3.12 microgram - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; alginic acid; maize starch; silicon dioxide; dl-alpha-tocopherol; sucrose; hydrolysed gelatin; hydrogenated soya oil - a source of calcium and vitamin d3 for use when dietary intake is inadequate. calcium and vitamin d3 are beneficial for the growth and maintenance of healthy bones and teeth. calcium supplements may be of assistance in the prevention of osteoporosis.